Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary in UK, Relonchem Limited, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its two products. The latest approvals are part of a broader string of UK MHRA authorizations received by Relonchem throughout the year. In August, Relonchem received marketing authorisation for three strengths of its Metformin Hydrochloride Relonchem Prolonged Release Tablets. In June 2025, the subsidiary secured marketing authorization for Oxybutynin hydrochloride 2.5mg/5ml Oral Solution. In late May, Relonchem received marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution, followed by approval for Sennosides 7.5 mg Tablets earlier in the month.